(VIANEWS) – Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) rose by a staggering 30.04% in 10 sessions from kr0.77 to kr1.00 at 13:39 EST on Friday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is sliding 0.66% to kr1,225.46, after four consecutive sessions in a row of losses.
NORDIC NANOVECTOR’s last close was kr0.90, 94.3% below its 52-week high of kr15.78.
About NORDIC NANOVECTOR
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-5.995.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -155.9%.
Moving Average
NORDIC NANOVECTOR’s worth is above its 50-day moving average of kr0.94 and way below its 200-day moving average of kr2.04.
More news about NORDIC NANOVECTOR (NANOV.OL).
